lipolysis is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-26. Numbers and descriptions here follow the published literature rather than marketing material.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Former SNP chief executive Peter Murrell appears before Edinburgh Sheriff Court charged with embezzlement, while his estranged wife, former Nicola Sturgeon, is told she will face no further action in the police investigation into SNP finances. Kemi Badenoch launches the Conservative local election campaign at an event in Buckinghamshire. Jo Coburn announces her departure from the BBC and as host of the programme BBC Politics Live. The 2025 City of London Corporation election is held in the City of London. 21 March – SNP MSP Fergus Ewing announces he will not stand for the party at the 2026 Holyrood election, but may run as an independent. Leaked messages deepen the row between Nigel Farage and Rupert Lowe. Rachel Reeves pledges no "tax and spend" in her spring statement. 22 March – The UK government is reported to be considering establishing "return hubs" for failed asylum seekers in the Balkans. 23 March – Chancellor Rachel Reeves confirms plans to reduce government running costs by 15% by the end of the decade. Steve Witkoff, the US special envoy to the Middle East, dismisses Starmer's plan for an international peacekeeping force to support a ceasefire in Ukraine as "a posture and a pose". 25 March – The UK government confirms it is ending a contract with Stay Belvedere Hotels to provide places for asylum seekers after an audit identified concerns about the firm's performance. A report by Jacqueline Perry KC finds "credible evidence" Rupert Lowe and his staff mistreated two female team members in ways that "seem to amount to harassment".
=== Preventing further liver damage === Regardless of the underlying cause of cirrhosis, consumption of alcohol and other potentially damaging substances is discouraged. There is no evidence that supports the avoidance or dose reduction of paracetamol in people with compensated cirrhosis; it is thus considered a safe analgesic for said individuals. Vaccination against hepatitis A and hepatitis B is recommended early in the course of illness due to a decline in effectiveness of the vaccines with decompensation. Treating the cause of cirrhosis prevents further damage; for example, giving oral antivirals such as entecavir and tenofovir where cirrhosis is due to hepatitis B prevents progression of cirrhosis. Similarly, control of weight and diabetes prevents deterioration in cirrhosis due to non-alcoholic fatty liver disease. People with cirrhosis or liver damage are often advised to avoid drugs that could further harm the liver. These include several drugs such as anti-depressants, certain antibiotics, and NSAIDs (like ibuprofen). These agents are hepatotoxic as they are metabolized by the liver. If a medication that harms the liver is still recommended by a doctor, the dosage can be adjusted to aim for minimal stress on the liver.
Breeding crops resistant, or at least less susceptible, to pest attacks. Releasing predators, parasitoids, or pathogens to control pest populations as a form of biological control. Chemical control like releasing pheromones into the field to confuse the insects into not being able to find mates and reproduce. Integrated Pest Management: using multiple techniques in tandem to achieve optimal results. Push-pull technique: intercropping with a "push" crop that repels the pest, and planting a "pull" crop on the boundary that attracts and traps it.
Individuals with Type 2 diabetes are often co-diagnosed with OSA, where Type 2 diabetes prevalence rates range between 15% and 30% within the OSA population. The relationship between OSA and Type 2 diabetes could be explained by the fact that OSA-characteristic fragmented sleep and irregular hypoxemia lead to the dysregulated metabolism of glucose in the blood. In particular, many polysomnography studies showed that OSA left untreated worsens glycemic control in individuals with Type 2 diabetes. However, it is possible that the relationship between OSA and Type 2 diabetes is bidirectional since diabetes-related nerve dysfunction may affect the respiratory system and induce breathing disturbances during sleep.
Sources: en.wikipedia.org
Creatine: one of the most popular nutritional supplements, it contributes to 400 million dollars in sales globally every year. It is a nonessential amino acid that helps to improve an athlete's performance during short-term, high intensity exercises such as weightlifting. Supplementation of creatine increases skeletal muscle creatine levels, boosting performance by increasing the rate at which adenosine triphosphate can be replenished from adenosine diphosphate, thereby increasing maximal power output. Potential side effects include gastrointestinal cramps, weight gain, fatigue, and diarrhea. Creatine is currently not recognized as a prohibited substance and can be purchased as a legal dietary supplement. β-hydroxy β-methylbutyrate, a metabolite of leucine also used as a supplement, has positive effects on lean muscle mass, possibly through a decrease in muscle catabolism. Human growth hormone (hGH): endogenous hormone that can help decrease fat mass while increasing lean body mass. hGH is one of the most commonly used substances among professional athletes because it has a small window for detection. It works by promoting the release of IGF-1, insulin-like growth factor, the release of which has anabolic effects on the body. Potential side effects include: cardiomyopathy, diabetes, renal failure, and hepatitis. If not prescribed by a professional, it is a banned substance in competition per WADA.
33,000, 25 October 2017 - The SENSEX closed at 33,042.50, for its first close above the 33,000 level. 34,000, 26 December 2017 - The SENSEX closed at 34,010.62, for its first close above the 34,000 level. 35,000, 17 January 2018 - The SENSEX closed at 35,081.82, for its first close above the 35,000 level. 36,000, 23 January 2018 - The SENSEX closed at 36,139.98, for its first close above the 36,000 level. 37,000, 27 July 2018 - The SENSEX on 26 July 2018 crossed the 37,000 mark for the first time during intra-day trading. On 27 July 2018 the index closed above the milestone. 38,000, 9 August 2018 - For the first time SENSEX passed the score of 38,000 during intra-day trading, and then closed at 38,024.37. 39,000, 1 April 2019 – The SENSEX on 1 April 2019 crossed the 39,000 mark for the first time during intra-day trading. 2 April 2019 – The SENSEX closed at 39,056.65, for its first close above the 39,000 level. 40,000, 23 May 2019 – The SENSEX crossed "40,000.100" at 10:45 AM for the first time. (2019 Loksabha (House of the People) Election results were getting published) 41,000, 26 November 2019 – The SENSEX crossed "41,120.28" first time during intraday trading. 42,000, 16 January 2020 - The SENSEX crossed 42,000 mark with an all-time high of 42,059.45 at around 09:47 AM. 45,000, 4 December 2020 - The SENSEX crossed 45,000 mark with an all-time high of 45,033 at around 10:30 AM. 46,000, 9 December 2020 - The SENSEX crossed 46,000 mark with an all-time high of 46,017 at around 1:30 PM.
==== Common equipment ==== Managing nutrient concentrations, oxygen saturation, and pH values within acceptable ranges is essential for successful hydroponic horticulture. Common tools used to manage hydroponic solutions include:
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.